GLP-1受体激动剂对炎症性皮肤病影响的综合综述
本综述旨在综合文献证据,分析GLP-1受体激动剂(GLP-1RA)对炎症性皮肤病的影响。GLP-1RA通过减轻体重、降低全身炎症,并主要通过与炎症信号通路和免疫细胞直接相互作用,可改善银屑病和化脓性汗腺炎(HS)。文中呈现了GLP-1RA在银屑病和HS患者中阳性作用的临床数据,并讨论了受其影响的免疫细胞和炎症通路。
要点
- GLP-1RA可能通过免疫调节和抗炎作用改善银屑病和化脓性汗腺炎。
- 临床数据支持GLP-1RA对银屑病和HS患者有积极效果。
- GLP-1RA的作用机制涉及直接与炎症信号通路和免疫细胞相互作用。
核心结论
- GLP-1RA可通过减重、降低全身炎症及直接免疫调节改善银屑病和化脓性汗腺炎。
研究设计与样本
- 综合综述,收集、分析并定量再综合关于GLP-1RA对炎症性皮肤病影响的文献证据。
主要发现
- GLP-1RA通过体重减少和全身炎症降低,以及直接与炎症信号通路和免疫细胞相互作用,改善银屑病和HS。
- 文中呈现了GLP-1RA在银屑病和HS患者中阳性作用的临床数据。
- 讨论了受GLP-1RA影响的免疫细胞和炎症通路。
临床怎么用
- 对于合并2型糖尿病或肥胖的银屑病或化脓性汗腺炎患者,GLP-1RA可能作为改善皮肤炎症的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide 1 receptor agonists (GLP-1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity. GLP-1RA have been found to be valuable therapeutic approaches not only for glucose control, but also for weight loss and cardiovascular risk reduction. It has also been established that GLP-1RA have immunological and anti-inflammatory effects. The aim of this article was to comprehensively review the literature and to collect, analyse and quantitatively resynthesize evidence on the possible effects of GLP-1RA on inflammatory skin diseases. Through body weight reduction and subsequent systemic inflammation reduction, but mainly through their direct interaction with signalling pathways of inflammation and immune cells, GLP-1RA can improve psoriasis and hidradenitis suppurativa (HS). Clinical data of the positive effects of GLP-1RA in patients with psoriasis and HS are presented. Moreover, the immune cells and inflammatory pathways affected by GLP-1RA are discussed.
引用
- Paschou IA, Sali E, Paschou SA, et al. The effects of GLP-1RA on inflammatory skin diseases: A comprehensive review. J Eur Acad Dermatol Venereol. 2025. PMID: 40298469. doi:10.1111/jdv.20694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。